Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.
paper
Cited
Public
Unavailable
- Authors
- Lin, Zhuofeng; Tian, Haishan; Lam, Karen S L; Lin, Shaoqiang; Hoo, Ruby C L; Konishi, Morichika; Itoh, Nobuyuki; Wang, Yu; Bornstein, Stefan R; Xu, Aimin; Li, Xiaokun
- Year
- 2013
- Journal
- Cell metabolism
- PMID
- 23663741
- DOI
- 10.1016/j.cmet.2013.04.005
Fibroblast growth factor 21 (FGF21) is a metabolic hormone with pleiotropic effects on regulating glucose and lipid homeostasis and insulin sensitivity. However, the mechanisms underlying the metabolic actions of FGF21 remain unknown. Here we show that the insulin-sensitizing adipokine adiponectin is a downstream effector of FGF21. Treatments with FGF21 enhanced both expression and secretion of adiponectin in adipocytes, thereby increasing serum levels of adiponectin in mice. Adiponectin knockout mice were refractory to several therapeutic benefits of FGF21, including alleviation of obesity-associated hyperglycemia, hypertriglyceridemia, insulin resistance, and hepatic steatosis. Furthermore, the effects of FGF21 on attenuation of obesity-induced impairment in insulin signaling in liver and skeletal muscle were abrogated in adiponectin knockout mice, whereas FGF21-mediated activation of ERK1/ERK2 in adipose tissues remained unaffected. Therefore, adiponectin couples FGF21 actions in local adipocytes to liver and skeletal muscle, thereby mediating the systemic effects of FGF21 on energy metabolism and insulin sensitivity.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | 2019 | 29568101 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Adipocyte-specific deletion of the mineralocorticoid receptor improves glucose homeostasis and associates with FGF21-adiponectin signalling in obese male mice. | Turner MB et al. | β | 2026 | β |
| Baicalein alleviates hepatic lipid metabolism disorders via the PPARΞ±-FGF21-adiponectin axis: Regulating crosstalk between the liver and adipose tissue. | Xia QS et al. | β | 2026 | β |
| Fibroblast growth factor 21 with molybdenum nanodots in a self-contracting thermosensitive hydrogel promotes diabetic wound repair by reprogramming lipid metabolism. | Zhang D et al. | β | 2026 | β |
| Interorgan crosstalk in metabolic dysfunction-associated steatotic liver disease. | Yang R et al. | β | 2026 | β |
| Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis-Related Fibrosis: Therapeutic Options and Approaches to Treatment. | Tincopa MA et al. | β | 2026 | β |
| Oral gene delivery platform based on glycol chitosan-PEG-lactoferrin conjugate. | Jang S et al. | β | 2026 | β |
| Research progress on the role and mechanism of traditional Chinese medicine based on "liver-multiple-organ interaction". | Yang C et al. | β | 2026 | β |
| The role of fibroblast growth factors in cell and cancerΒ metabolism. | Price J et al. | β | 2026 | β |
| The role of lipid metabolism disorder in the progression and treatment of ocular vascular diseases. | Song W et al. | β | 2026 | β |
| Activating transcription factor 4 mediates rare sugar-induced transactivation of the fibroblast growth factor 21 promoter. | Efendi OGHNB et al. | β | 2025 | β |
| Adipokine and Hepatokines in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current and Developing Trends. | Pezzino S et al. | β | 2025 | β |
| Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study. | Ozkan B et al. | β | 2025 | β |
| [Advances in pharmacological research for retinopathy of prematurity]. | Xie Y et al. | β | 2025 | β |
| ANGPTL3 nanobody-FGF21 fusion protein ameliorates metabolic dysfunction-associated fatty liver disease via regulation of lipid and glucose metabolism and attenuation of oxidative stress. | Zhang Y et al. | β | 2025 | β |
| Associations among serum FGF21 levels, inflammation, and metabolic dysfunction-associated steatotic liver disease: mediation analyses in a Chinese community-based population. | Tan H et al. | β | 2025 | β |
| Beta-Klotho Protein Expression in Healthy Human Tissues and Liver Biopsies From Patients With MASLD or MASH. | Aaldijk AS et al. | β | 2025 | β |
| Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH. | Raji A et al. | β | 2025 | β |
| Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus. | Holleboom AG et al. | β | 2025 | β |
| Decoding the Multiple Identities and Crosstalk of Organokines in Obesity-Related Type 2 Diabetes Mellitus. | Ni YQ et al. | β | 2025 | β |
| Development of FGF21 Mutant with Potent Cardioprotective Effects in T2D Mice via FGFR1-AMPK-Mediated Inhibition of Oxidative Stress. | Peng Z et al. | β | 2025 | β |
| Dietary caloric input and tumor growth accelerate senescence and modulate liver and adipose tissue crosstalk. | Nascimento JΓΊnior JXD et al. | β | 2025 | β |
| DsbA-L: A Promising Therapeutic Target for Metabolic Diseases. | Yang M et al. | β | 2025 | β |
| Effects and Safety of FGF21 Analogs on Glycemic Parameters, Lipid Profiles, and Adiponectin in Overweight and Obese Adults: A Meta-Analysis of Randomized Controlled Trials. | Nie Z et al. | β | 2025 | β |
| Effects of High-Protein Nutritional Guidance on Sarcopenia-Related Parameters in Individuals Aged β₯ 75 Years with Type 2 Diabetes: An Exploratory Single-Arm Pre-Post Intervention Study. | Todoroki H et al. | β | 2025 | β |
| Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients. | Xu J et al. | β | 2025 | β |
| Emerging role of E4BP4/NFIL3 in metabolic homeostasis. | Ran S et al. | β | 2025 | β |
| Enhanced paracrine action of FGF21 in stromal cells delays thymic aging. | Youm YH et al. | β | 2025 | β |
| Exerkines and Sarcopenia: Unveiling the Mechanism Behind Exercise-Induced Mitochondrial Homeostasis. | Wang J et al. | β | 2025 | β |
| FGF21-MAPK1 Imbalance Disrupts Hepatic Lipid Metabolism in Dairy Cow Ketosis. | Xu JJ et al. | β | 2025 | β |
| FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice. | Zhang K et al. | β | 2025 | β |
| FGF21 reverses MASH through coordinated actions on the CNS and liver. | Rose JP et al. | β | 2025 | β |
| Genetic diversity and dietary adaptations of the Central Plains Han Chinese population in East Asia. | Qiao X et al. | β | 2025 | β |
| Hepatic ChREBP reciprocally modulates systemic insulin sensitivity in NAFLD. | Sen A et al. | β | 2025 | β |
| Hepatic ENTPD5 Is Critical for Maintaining Metabolic Homeostasis and Promoting Brown Adipose Tissue Thermogenesis. | Ma R et al. | β | 2025 | β |
| Hepatokines and their role in cardiohepatic interactions in heart failure. | Shouman WA et al. | β | 2025 | β |
| Integrative Strategies for Preventing and Managing Metabolic Syndrome: The Impact of Exercise and Diet on Oxidative Stress Reduction-A Review. | Onu A et al. | β | 2025 | β |
| Melinjo-derived Gnetin C restores metabolic balance via dual adipose and hepatic effects in high-fat diet mice. | Kishimoto T et al. | β | 2025 | β |
| Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass. | Isakov V | β | 2025 | β |
| Multimodal Therapeutic Strategies Targeting BCAA Metabolism in Diabetic Cardiomyopathy: A Path to Cardioprotection. | Chetana S et al. | β | 2025 | β |
| Myokines as potential mediators of changes in glucose homeostasis and muscle mass after bariatric surgery. | Orioli L et al. | β | 2025 | β |
| Pentraxin 3 ameliorates glucocorticoid-induced osteonecrosis of the femoral head via TLR4/NF-ΞΊB/FGF21 signaling axis. | Li J et al. | β | 2025 | β |
| Phytotherapy for Obesity Management: The Role of Gut Microbiota in Reshaping Adipose Tissue. | Wang H et al. | β | 2025 | β |
| Research progress on the role of FGF21 in insulin resistance. | Zhang H et al. | β | 2025 | β |
| RhFGF21 protects the skin from UVB irradiation in diabetic mice through the inhibition of epidermal cell apoptosis and macrophage-mediated inflammation via the SIRT1 signaling pathway. | Ye S et al. | β | 2025 | β |
| Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. | Xiang L et al. | β | 2025 | β |
| Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions. | Wang T et al. | β | 2025 | β |
| Stimuli-responsive hydrogel with spatiotemporal co-delivery of FGF21 and HβS for synergistic diabetic wound repair. | Chu L et al. | β | 2025 | β |
| Systemic Changes in Adults With a Fontan Circulation: Insights From the Plasma Proteome. | Kelly B et al. | β | 2025 | β |
| Targeting fibroblast growth factor (FGF)-21: a promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. | Cui X et al. | β | 2025 | β |
| Time-restricted feeding mitigates HFD-induced sarcopenic obesity in aging mice through improving the sensitivity of FGF21. | Wang T et al. | β | 2025 | β |
| Timing of exercise differentially impacts adipose tissue gain in male adolescent rats. | Kutsenko Y et al. | β | 2025 | β |
| TSG attenuated NAFLD and facilitated weight loss in HFD-fed mice via activating the RUNX1/FGF21 signaling axis. | Huang ZL et al. | β | 2025 | β |
| Whole-brain Mapping Reveals Diet-dependent Neuronal Activation and Selective Resistance to Exogenous FGF21. | Meng J et al. | β | 2025 | β |
| Adipokines and their role in acute pancreatitis. | Rafaqat S et al. | β | 2024 | β |
| Adipose c-Jun NH2-terminal kinase promotes angiotensin II-induced and deoxycorticosterone acetate salt-induced hypertension and vascular dysfunction by inhibition of adiponectin production and activation of SGK1 in mice. | Gan J et al. | β | 2024 | β |
| Aging adipose tissue, insulin resistance, and type 2 diabetes. | Zhao Y et al. | β | 2024 | β |
| A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages. | Ji Y et al. | β | 2024 | β |
| Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism. | Yang Z et al. | β | 2024 | β |
| Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity. | Liang Y et al. | β | 2024 | β |
| Endocrine fibroblast growth factors in domestic animals. | Brinker EJ et al. | β | 2024 | β |
| Exerkines and cardiometabolic benefits of exercise: from bench to clinic. | Jin L et al. | β | 2024 | β |
| Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease. | Chen Y et al. | β | 2024 | β |
| FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond. | Harrison SA et al. | β | 2024 | β |
| FGF21 mediating the Sex-dependent Response to Dietary Macronutrients. | Soto Sauza KA et al. | β | 2024 | β |
| Fibroblast growth factor 21 alleviates acetaminophen induced acute liver injury by activating Sirt1 mediated autophagy. | Xu G et al. | β | 2024 | β |
| Fibroblast growth factor 21 alleviates diabetes-induced cognitive decline. | Zhang X et al. | β | 2024 | β |
| Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway. | Zhou C et al. | β | 2024 | β |
| Fibroblast Growth Factors in Cardiovascular Disease. | Morita H et al. | β | 2024 | β |
| Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. | Bo T et al. | β | 2024 | β |
| Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. | Chui ZSW et al. | β | 2024 | β |
| Influence of Adipokines on Metabolic Dysfunction and Aging. | Park S et al. | β | 2024 | β |
| Insights into the role of FGF21 in coronary heart disease. | Zhang QY et al. | β | 2024 | β |
| Involvement of the vagus nerve and hepatic gene expression in serum adiponectin concentrations in mice. | Hashimoto N et al. | β | 2024 | β |
| Maternal nutrient metabolism in the liver during pregnancy. | Fang H et al. | β | 2024 | β |
| Mesenchymal Stem Cell-Derived Exosomes Attenuate Hepatic Steatosis and Insulin Resistance in Diet-Induced Obese Mice by Activating the FGF21-Adiponectin Axis. | Kim B et al. | β | 2024 | β |
| Murine nuclear tyrosyl-tRNA synthetase deficiency leads to fat storage deficiency and hearing loss. | Jones JA et al. | β | 2024 | β |
| Myokines: metabolic regulation in obesity and type 2 diabetes. | Chen ZT et al. | β | 2024 | β |
| New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease. | Zhang J et al. | β | 2024 | β |
| New advances of adiponectin in regulating obesity and related metabolic syndromes. | Han Y et al. | β | 2024 | β |
| New and emerging treatments for metabolic dysfunction-associated steatohepatitis. | Tincopa MA et al. | β | 2024 | β |
| Non-alcoholic fatty liver disease promotes breast cancer progression through upregulated hepatic fibroblast growth factor 21. | Sui Y et al. | β | 2024 | β |
| [Non-classical hormones from the fibroblast growth factor family]. | Gronskaia SA et al. | β | 2024 | β |
| Novel FGF21 analogues through structure-based optimization for therapeutic development. | Guo Y et al. | β | 2024 | β |
| Organophosphorus Flame Retardants and Metabolic Disruption: An <i>in Silico</i>, <i>in Vitro</i>, and <i>in Vivo</i> Study Focusing on Adiponectin Receptors. | Liu Y et al. | β | 2024 | β |
| Relationship of fibroblast growth factor 21, Klotho, and diabetic retinopathy: a meta-analysis. | Jiang Y et al. | β | 2024 | β |
| Sex-specific impact of <i>GCKR</i> rs1260326 polymorphism on metabolic traits in an older Japanese population: the Bunkyo Health Study. | Sakamoto S et al. | β | 2024 | β |
| Shared signaling pathways and targeted therapy by natural bioactive compounds for obesity and type 2 diabetes. | Tian S et al. | β | 2024 | β |
| The association between fibroblast growth factor 21 with diabetes retinopathy among type 2 diabetes mellitus patients: a systematic review, meta-analysis, and meta-regression. | Basir H et al. | β | 2024 | β |
| The Different Shades of Thermogenic Adipose Tissue. | Hu Y et al. | β | 2024 | β |
| The Role of Exerkines in Obesity-Induced Disruption of Mitochondrial Homeostasis in Thermogenic Fat. | Shao H et al. | β | 2024 | β |
| The role of FGF21 in the interplay between obesity and non-alcoholic fatty liver disease: a narrative review. | Negroiu CE et al. | β | 2024 | β |
| The secretory function of adipose tissues in metabolic regulation. | Liu Y et al. | β | 2024 | β |
| Transitions in chromatin conformation shaped by fatty acids and the circadian clock underlie hepatic transcriptional reorganization in obese mice. | Pacheco-Bernal I et al. | β | 2024 | β |
| Transplantation of committed pre-adipocytes from brown adipose tissue improves whole-body glucose homeostasis. | Dewal RS et al. | β | 2024 | β |
| Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8<sup>+</sup>TΒ cells. | Hu C et al. | β | 2024 | β |
| Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids. | Fiorenza M et al. | β | 2024 | β |
| Adipokines in atherosclerosis: unraveling complex roles. | Luo J et al. | β | 2023 | β |
| Adipokines in glucose and lipid metabolism. | Wang X et al. | β | 2023 | β |
| Adipose tissue adipokines and lipokines: Functions and regulatory mechanism in skeletal muscle development and homeostasis. | Gu X et al. | β | 2023 | β |
| Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease. | Chikamatsu M et al. | β | 2023 | β |
| AMPK and the Endocrine Control of Metabolism. | Townsend LK et al. | β | 2023 | β |
| A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. | Harrison SA et al. | β | 2023 | β |
| Association of triglyceride-glucose index with myocardial injury post-stroke in older patients with first-ever ischemic stroke. | Niu M et al. | β | 2023 | β |
| Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho. | Aaldijk AS et al. | β | 2023 | β |
| Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines. | Berezin AA et al. | β | 2023 | β |
| Ceramide on the road to insulin resistance and immunometabolic disorders in transition dairy cows: driver or passenger? | Zhao Y et al. | β | 2023 | β |
| Chronic docosahexaenoic acid supplementation improves metabolic plasticity in subcutaneous adipose tissue of aged obese female mice. | FΓ©lix-Soriano E et al. | β | 2023 | β |
| Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. | Alkhouri N et al. | β | 2023 | β |
| Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats. | Huang X et al. | β | 2023 | β |
| Current, emerging, and potential therapies for non-alcoholic steatohepatitis. | Yang Z et al. | β | 2023 | β |
| FGF21 protects against doxorubicin-induced cardiotoxicity by inhibiting connexin 43 ubiquitination. | Huang Y et al. | β | 2023 | β |
| FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis. | Liu C et al. | β | 2023 | β |
| Fibroblast Growth Factor 21: A Fascinating Perspective on the Regulation of Muscle Metabolism. | Li S et al. | β | 2023 | β |
| Fibroblast growth factor 21 in heart failure. | Tucker W et al. | β | 2023 | β |
| Fibroblast growth factor 21 in metabolic syndrome. | Yang M et al. | β | 2023 | β |
| Fibroblast growth factor 21 is an independent predictor of prevalent and incident obstructive sleep apnea. | Huang W et al. | β | 2023 | β |
| Fibroblast growth factor receptor 1/KlothoΞ² agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. | Wong C et al. | β | 2023 | β |
| Focus on Alzheimer's Disease: The Role of Fibroblast Growth Factor 21 and Autophagy. | Yang L et al. | β | 2023 | β |
| Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective. | Zhang Y et al. | β | 2023 | β |
| Fucoidan from Sargassum thunbergii obtained via step gradient ethanol precipitation indicate potential anti-obesity and anti-hepatic steatosis in vitro 3T3-L1 and HepG2 cells and in vivo high-fat diet-induced obesity mice. | Lee HG et al. | β | 2023 | β |
| Hepatic G Protein-Coupled Receptor 180 Deficiency Ameliorates High Fat Diet-Induced Lipid Accumulation via the Gi-PKA-SREBP Pathway. | Zhang Y et al. | β | 2023 | β |
| Hepatic-Specific FGF21 Knockout Abrogates Ovariectomy-Induced Obesity by Reversing Corticosterone Production. | Xu J et al. | β | 2023 | β |
| Hepatic transcript profiling in beef cattle: Effects of rumen-protected niacin supplementation. | Alfaro GF et al. | β | 2023 | β |
| Hepatocellular carcinoma induced by hepatocyte Pten deletion reduces BAT UCP-1 and thermogenic capacity in mice, despite increasing serum FGF-21 and iWAT browning. | Peixoto ΓS et al. | β | 2023 | β |
| Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients. | Franck M et al. | β | 2023 | β |
| Impact of omega-3 fatty acids supplementation on the gene expression of peroxisome proliferator activated receptors-<i>Ξ³</i>, <i>Ξ±</i> and fibroblast growth factor-21 serum levels in patients with various presentation of metabolic conditions: a GRADE assessed systematic review and dose-response meta-analysis of clinical trials. | Ahmadi AR et al. | β | 2023 | β |
| Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes. | Liu Z et al. | β | 2023 | β |
| Insight to the association among fibroblast growth factor 21, non-alcoholic fatty liver disease and cardiovascular outcomes: A population-based study. | Shen Y et al. | β | 2023 | β |
| Intermittent fasting favorably modulates adipokines and potentially attenuates atherosclerosis. | Al Zein M et al. | β | 2023 | β |
| Interplay of skeletal muscle and adipose tissue: sarcopenic obesity. | Park MJ et al. | β | 2023 | β |
| Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology. | Zhao J et al. | β | 2023 | β |
| Liver-derived FGF21 is required for the effect of time-restricted feeding on high-fat diet-induced fatty liver in mice. | Hua L et al. | β | 2023 | β |
| Longitudinal Associations of Dietary Fiber Intake with Glycated Hemoglobin and Estimated Insulin Sensitivity in Adults with and without Type 1 Diabetes. | Basu A et al. | β | 2023 | β |
| Modulating effects of capsaicin on glucose homeostasis and the underlying mechanism. | Liang W et al. | β | 2023 | β |
| Mulberry leaf flavonoids activate BAT and induce browning of WAT to improve type 2 diabetes via regulating the AMPK/SIRT1/PGC-1Ξ± signaling pathway. | Cheng L et al. | β | 2023 | β |
| New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. | Yang K et al. | β | 2023 | β |
| Role and mechanism of PVN-sympathetic-adipose circuit in depression and insulin resistance induced by chronic stress. | Wang J et al. | β | 2023 | β |
| Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. | Loomba R et al. | β | 2023 | β |
| Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice. | Feng JN et al. | β | 2023 | β |
| Signaling pathways and intervention for therapy of type 2 diabetes mellitus. | Cao R et al. | β | 2023 | β |
| The Interplay of Adipokines and Pancreatic Beta Cells in Metabolic Regulation and Diabetes. | Kim J et al. | β | 2023 | β |
| The pan-liver network theory: From traditional chinese medicine to western medicine. | Zhang Y et al. | β | 2023 | β |
| Thermoneutrality or standard temperature: is there an ideal housing temperature to study the antisteatotic effects of green tea in obese mice? | Silva V et al. | β | 2023 | β |
| Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form. | Crudele L et al. | β | 2023 | β |
| Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention. | Zhu Y et al. | β | 2022 | β |
| Acute retinol mobilization by retinol-binding protein 4 in mouse liver induces fibroblast growth factor 21 expression. | Steinhoff JS et al. | β | 2022 | β |
| Adipokines: Deciphering the cardiovascular signature of adipose tissue. | Galley JC et al. | β | 2022 | β |
| Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation. | Ren Y et al. | β | 2022 | β |
| Adiponectin deficiency promotes endometrial carcinoma pathogenesis and development via activation of mitogen-activated protein kinase. | Yan Y et al. | β | 2022 | β |
| Aerobic exercise regulates FGF21 and NLRP3 inflammasome-mediated pyroptosis and inhibits atherosclerosis in mice. | Li XH et al. | β | 2022 | β |
| Alcoholic fatty liver is blunted by rFGF21 administration in mice lacking adipose FGFR1: The role of FGF21 in PPARΞ±-mediated regulation of adipose tissue mass. | Xu Y et al. | β | 2022 | β |
| Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. | MarchianΓ² S et al. | β | 2022 | β |
| Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021. | She QY et al. | β | 2022 | β |
| Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. | Machado SA et al. | β | 2022 | β |
| Change of Fibroblast Growth Factor 21 Level Correlates with the Severity of Diabetic Sensory Polyneuropathy after Six-Week Physical Activity. | MolnΓ‘r Γ et al. | β | 2022 | β |
| Circadian Clock Desynchronization and Insulin Resistance. | Catalano F et al. | β | 2022 | β |
| Coffee peel extracts ameliorate non-alcoholic fatty liver disease <i>via</i> a fibroblast growth factor 21-adiponectin signaling pathway. | Fan Z et al. | β | 2022 | β |
| Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice. | Liu D et al. | β | 2022 | β |
| Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating fibroblast growth factor 21-adiponectin axis. | Guo XF et al. | β | 2022 | β |
| Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development. | Singh DD et al. | β | 2022 | β |
| Do Sugar-Sweetened Beverages Increase Fasting FGF21 Irrespective of the Type of Added Sugar? A Secondary Exploratory Analysis of a Randomized Controlled Trial. | Geidl-Flueck B et al. | β | 2022 | β |
| Emerging roles of fibroblast growth factor 21 in critical disease. | Yan F et al. | β | 2022 | β |
| Exerkines in health, resilience and disease. | Chow LS et al. | β | 2022 | β |
| Exposure to outdoor and indoor air pollution and risk of overweight and obesity across different life periods: A review. | Shi X et al. | β | 2022 | β |
| FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance. | SzczepaΕska E et al. | β | 2022 | β |
| FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk. | Chaffin AT et al. | β | 2022 | β |
| FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity. | Jin L et al. | β | 2022 | β |
| Fibroblast growth factor-21 improves insulin action in nonlactating ewes. | Lamb CL et al. | β | 2022 | β |
| Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients: A Prospective Cohort Study. | Billeter AT et al. | β | 2022 | β |
| Genetically predicted adiponectin causally reduces the risk of chronic kidney disease, a bilateral and multivariable mendelian randomization study. | Wu R et al. | β | 2022 | β |
| Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. | Qiao L et al. | β | 2022 | β |
| Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers. | Sui Y et al. | β | 2022 | β |
| Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk. | Berthou F et al. | β | 2022 | β |
| Liver-adipose tissue crosstalk in alcohol-associated liver disease: The role of mTOR. | Rodriguez Y et al. | β | 2022 | β |
| Liver Brain Interactions: Focus on FGF21 a Systematic Review. | Prida E et al. | β | 2022 | β |
| Methionine restriction - Association with redox homeostasis and implications on aging and diseases. | Zhang Y et al. | β | 2022 | β |
| Multi-organ FGF21-FGFR1 signaling in metabolic health and disease. | Kaur N et al. | β | 2022 | β |
| Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown. | Iacob SA et al. | β | 2022 | β |
| Novel dual PPARΞ±/Ξ³ agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects. | Guru B et al. | β | 2022 | β |
| Nutraceutical Prevention of Diabetic Complications-Focus on Dicarbonyl and Oxidative Stress. | McCarty MF et al. | β | 2022 | β |
| Parathyroid hormone-related protein prevents high-fat-diet-induced obesity, hepatic steatosis and insulin resistance in mice. | Qin B et al. | β | 2022 | β |
| Performance and Metabolic, Inflammatory, and Oxidative Stress-Related Parameters in Early Lactating Dairy Cows with High and Low Hepatic FGF21 Expression. | Gessner DK et al. | β | 2022 | β |
| Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. | Liu C et al. | β | 2022 | β |
| Phosphorylation of RXRΞ± mediates the effect of JNK to suppress hepatic FGF21 expression and promote metabolic syndrome. | Vernia S et al. | β | 2022 | β |
| Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. | Mehan S et al. | β | 2022 | β |
| Rutin-activated adipose tissue thermogenesis is correlated with increased intestinal short-chain fatty acid levels. | Cheng L et al. | β | 2022 | β |
| Serum FGF21 Levels Predict the MACE in Patients With Myocardial Infarction After Coronary Artery Bypass Graft Surgery. | Xie W et al. | β | 2022 | β |
| Symposium review: Adipose tissue endocrinology in the periparturient period of dairy cows. | HΓ€ussler S et al. | β | 2022 | β |
| The Nrf2 in Obesity: A Friend or Foe? | Xia Y et al. | β | 2022 | β |
| The potential function and clinical application of FGF21 in metabolic diseases. | Chen Z et al. | β | 2022 | β |
| The relationship between sarcopenia detected in newly diagnosed colorectal cancer patients and FGF21, irisin and CRP levels. | Oflazoglu U et al. | β | 2022 | β |
| The Role of Crosstalk between Adipose Cells and Myocytes in the Pathogenesis of Sarcopenic Obesity in the Elderly. | Zamboni M et al. | β | 2022 | β |
| Transcriptome Comparison Reveals the Difference in Liver Fat Metabolism between Different Sheep Breeds. | Li T et al. | β | 2022 | β |
| Adiponectin-expressing Treg facilitate T lymphocyte development in thymic nurse cell complexes. | Zhang Y et al. | β | 2021 | β |
| Advances in Biological Functions and Clinical Studies of FGF21. | Lin W et al. | β | 2021 | β |
| A feed-forward regulatory loop in adipose tissue promotes signaling by the hepatokine FGF21. | Han MS et al. | β | 2021 | β |
| Age-adjusted mortality from pancreatic cancer increased NINE-FOLD in japan from 1950 to 1995 - Was a low-protein quasi-vegan diet a key factor in their former low risk? | McCarty MF et al. | β | 2021 | β |
| A glimpse at the metabolic research in China. | Chen XW et al. | β | 2021 | β |
| Association between FGF19, FGF21 and lipocalin-2, and diabetes progression in PCOS. | Cheng F et al. | β | 2021 | β |
| Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes. | Jin S et al. | β | 2021 | β |
| Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtype: A Case-Control Study. | Wang N et al. | β | 2021 | β |
| A stem cell based <i>in vitro</i> model of NAFLD enables the analysis of patient specific individual metabolic adaptations in response to a high fat diet and AdipoRon interference. | Graffmann N et al. | β | 2021 | β |
| Attenuation of FGF21 signalling might aggravate the impairment of glucose homeostasis during the high sucrose diet induced transition from prediabetes to diabetes in WNIN/GR-Ob rats. | Kondeti S et al. | β | 2021 | β |
| Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies. | Hua S et al. | β | 2021 | β |
| Beyond the Liver: Liver-Eye Communication in Clinical and Experimental Aspects. | Yuan TH et al. | β | 2021 | β |
| Bile acids and their receptors in metabolic disorders. | Fiorucci S et al. | β | 2021 | β |
| Comparative Analysis of MicroRNA Expression Profiles Between Skeletal Muscle- and Adipose-Derived Exosomes in Pig. | Li W et al. | β | 2021 | β |
| Contributions of white and brown adipose tissues to the circadian regulation of energy metabolism. | Heyde I et al. | β | 2021 | β |
| Deficiency of Cathelicidin Attenuates High-Fat Diet Plus Alcohol-Induced Liver Injury through FGF21/Adiponectin Regulation. | Li F et al. | β | 2021 | β |
| Dimethyl itaconate attenuates palmitate-induced insulin resistance in skeletal muscle cells through the AMPK/FGF21/PPARΞ΄-mediated suppression of inflammation. | Park SY et al. | β | 2021 | β |
| Emerging synthetic drugs for the treatment of liver cirrhosis. | Fallowfield JA et al. | β | 2021 | β |
| Erythropoietin Non-hematopoietic Tissue Response and Regulation of Metabolism During Diet Induced Obesity. | Dey S et al. | β | 2021 | β |
| Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis. | Galal A et al. | β | 2021 | β |
| FGF19 and FGF21: In NASH we trust. | Talukdar S et al. | β | 2021 | β |
| FGF21/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China. | Liu D et al. | β | 2021 | β |
| FGF21 promotes ischaemic angiogenesis and endothelial progenitor cells function under diabetic conditions in an AMPK/NAD+-dependent manner. | Dai Q et al. | β | 2021 | β |
| FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. | Wang Y et al. | β | 2021 | β |
| Fibroblast growth factor 21 in dairy cows: current knowledge and potential relevance. | Eder K et al. | β | 2021 | β |
| Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication. | Liu W et al. | β | 2021 | β |
| Hepatic P38 Activation Modulates Systemic Metabolism Through Fgf21-Mediated Interorgan Communication. | Liu W et al. | β | 2021 | β |
| <i>Lactobacillus acidophilus</i> NX2-6 Improved High-Fat Diet-Induced Glucose Metabolism Disorder Independent of Promotion of Insulin Secretion in Mice. | Tang C et al. | β | 2021 | β |
| Ileal transposition helps to regulate plasma hepatokine levels in obese Zucker (Crl:ZUC(ORL)-Lepr<sup>fa</sup>) rats. | Stygar D et al. | β | 2021 | β |
| Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice. | Zhang N et al. | β | 2021 | β |
| Malnutrition in Older Adults-Recent Advances and Remaining Challenges. | Norman K et al. | β | 2021 | β |
| Metabolic Disturbances in Rat Sublines with Constitutionally Altered Serotonin Homeostasis. | KesiΔ M et al. | β | 2021 | β |
| Metabolic Messengers: FGF21. | Flippo KH et al. | β | 2021 | β |
| Organ-organ communication: The liver's perspective. | Wang F et al. | β | 2021 | β |
| PPARΞ± agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. | Xu Y et al. | β | 2021 | β |
| Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus. | Guo C et al. | β | 2021 | β |
| Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver-Adipose Tissue Crosstalk. | MorΓ‘n-Costoya A et al. | β | 2021 | β |
| Short and long-term effects of high-intensity interval training applied alone or with whole-body cryostimulation on glucose homeostasis and myokine levels in overweight to obese subjects. | KozΕowska-Flis M et al. | β | 2021 | β |
| Skeletal Muscle and Bone - Emerging Targets of Fibroblast Growth Factor-21. | Sun H et al. | β | 2021 | β |
| Spinal Cord Injury Reduces Serum Levels of Fibroblast Growth Factor-21 and Impairs Its Signaling Pathways in Liver and Adipose Tissue in Mice. | Liu XH et al. | β | 2021 | β |
| The autophagy protein Becn1 improves insulin sensitivity by promoting adiponectin secretion via exocyst binding. | Kuramoto K et al. | β | 2021 | β |
| The Effect of FGF21 and Its Genetic Variants on Food and Drug Cravings, Adipokines and Metabolic Traits. | Epperlein S et al. | β | 2021 | β |
| Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. | Kumar V et al. | β | 2021 | β |
| The Role of Anti-Inflammatory Adipokines in Cardiometabolic Disorders: Moving beyond Adiponectin. | Jung HN et al. | β | 2021 | β |
| The serum fibroblast growth factor 21 is correlated with retinopathy in patients with type 2 diabetes mellitus. | Heidari Z et al. | β | 2021 | β |
| Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. | Nauck MA et al. | β | 2021 | β |
| Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice. | Queen NJ et al. | β | 2021 | β |
| AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients. | Kaufman A et al. | β | 2020 | β |
| A novel selective PPARΞ± modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. | Kawanishi H et al. | β | 2020 | β |
| Antibody-mediated activation of the FGFR1/KlothoΞ² complex corrects metabolic dysfunction and alters food preference in obese humans. | Baruch A et al. | β | 2020 | β |
| Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. | Marchelek-Mysliwiec M et al. | β | 2020 | β |
| Circulating FGF21 Levels in Human Health and Metabolic Disease. | Keuper M et al. | β | 2020 | β |
| CREBH Improves Diet-Induced Obesity, Insulin Resistance, and Metabolic Disturbances by FGF21-Dependent and FGF21-Independent Mechanisms. | Satoh A et al. | β | 2020 | β |
| Dietary Methionine Restriction Signals to the Brain Through Fibroblast Growth Factor 21 to Regulate Energy Balance and Remodeling of Adipose Tissue. | Forney LA et al. | β | 2020 | β |
| Effect of Fibroblast Growth Factor 21 on the Development of Atheromatous Plaque and Lipid Metabolic Profiles in an Atherosclerosis-Prone Mouse Model. | Maeng HJ et al. | β | 2020 | β |
| FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human. | Henriksson E et al. | β | 2020 | β |
| FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | Tillman EJ et al. | β | 2020 | β |
| FGF21 Mimics a Fasting-Induced Metabolic State and Increases Appetite in Zebrafish. | Blanco AM et al. | β | 2020 | β |
| FGF/FGFR signaling in health and disease. | Xie Y et al. | β | 2020 | β |
| Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. | Wu L et al. | β | 2020 | β |
| Fibroblast Growth Factor-21, Leptin, and Adiponectin Responses to Acute Cold-Induced Brown Adipose Tissue Activation. | Sun L et al. | β | 2020 | β |
| Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity. | Tas E et al. | β | 2020 | β |
| Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma. | Ocker M | β | 2020 | β |
| <i>In vivo</i> protective effect of adipsin-deficiency on spontaneous knee osteoarthritis in aging mice. | ParΓ© F et al. | β | 2020 | β |
| Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. | Majeed M et al. | β | 2020 | β |
| Organokines in disease. | Chung HS et al. | β | 2020 | β |
| Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. | Liu Q et al. | β | 2020 | β |
| Pulse Wave Velocity Is Associated with Increased Plasma oxLDL in Ageing but Not with FGF21 and Habitual Exercise. | Lee SY et al. | β | 2020 | β |
| Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. | Yung JHM et al. | β | 2020 | β |
| Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation. | Dey S et al. | β | 2020 | β |
| Targeting Neurovascular Interaction in Retinal Disorders. | Fu Z et al. | β | 2020 | β |
| The Effects of B1344, a Novel Fibroblast Growth Factor 21 Analog, on Nonalcoholic Steatohepatitis in Nonhuman Primates. | Cui A et al. | β | 2020 | β |
| The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines. | Field BC et al. | β | 2020 | β |
| The Role of Exercise in the Interplay between Myokines, Hepatokines, Osteokines, Adipokines, and Modulation of Inflammation for Energy Substrate Redistribution and Fat Mass Loss: A Review. | Gonzalez-Gil AM et al. | β | 2020 | β |
| The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. | Geng L et al. | β | 2020 | β |
| Valine Supplementation Does Not Reduce Lipid Accumulation and Improve Insulin Sensitivity in Mice Fed High-Fat Diet. | Ma Q et al. | β | 2020 | β |
| Weight Loss and Concomitant Adipose Autophagy in Methionine-Restricted Obese Mice is Not Dependent on Adiponectin or FGF21. | Cooke D et al. | β | 2020 | β |
| Adipocytokines in Steatotic Liver Surgery/Transplantation. | JimΓ©nez-Castro MB et al. | β | 2019 | β |
| A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21. | Kliewer SA et al. | β | 2019 | β |
| An overview of energy and metabolic regulation. | Wen S et al. | β | 2019 | β |
| Ascorbic acid attenuates cell stress by activating theΒ fibroblast growth factor 21/fibroblast growth factor receptorΒ 2/adiponectin pathway in HepG2 cells. | Gu X et al. | β | 2019 | β |
| Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. | DiNicolantonio JJ et al. | β | 2019 | β |
| Astaxanthin plus berberine: a nutraceutical strategy for replicating the benefits of a metformin/fibrate regimen in metabolic syndrome. | DiNicolantonio JJ et al. | β | 2019 | β |
| Author response to 'Problems associated with a highly artificial ketogenic diet: Letter to the Editor Re: van der Louw EJTM, Olieman JF, van den Bemt PMLA, <i>et al.</i> "Ketogenic diet treatment as adjuvant to standard treatment of glioblastoma multiforme: a feasibility and safety study"'. | van der Louw EJ et al. | β | 2019 | β |
| Beige Fat, Adaptive Thermogenesis, and Its Regulation by Exercise and Thyroid Hormone. | Phillips KJ | β | 2019 | β |
| Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. | Funcke JB et al. | β | 2019 | β |
| Cardiac myocyte KLF5 regulates body weight via alteration of cardiac FGF21. | Pol CJ et al. | β | 2019 | β |
| CYP2A6 is associated with obesity: studies in human samples and a high fat diet mouse model. | Wang K et al. | β | 2019 | β |
| Cytokines and Abnormal Glucose and Lipid Metabolism. | Shi J et al. | β | 2019 | β |
| Dietary methionine restriction improves glucose metabolism in the skeletal muscle of obese mice. | Luo T et al. | β | 2019 | β |
| Dyslipidemia in retinal metabolic disorders. | Fu Z et al. | β | 2019 | β |
| Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. | Brown M et al. | β | 2019 | β |
| Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues. | Geng L et al. | β | 2019 | β |
| Exercise ameliorates the FGF21-adiponectin axis impairment in diet-induced obese mice. | Yang W et al. | β | 2019 | β |
| Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer's disease. | Chen S et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 and Browning of White Adipose Tissue. | Cuevas-Ramos D et al. | β | 2019 | β |
| Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats. | Shi Y et al. | β | 2019 | β |
| Fibroblast growth factor 21 coordinates adiponectin to mediate the beneficial effects of low-protein diet on primordial follicle reserve. | Zhuo Y et al. | β | 2019 | β |
| Fibroblast growth factor 21 in non-alcoholic fatty liver disease. | Tucker B et al. | β | 2019 | β |
| Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic Ξ²-cell dysfunction via regulation of AMPK signaling and lipid metabolism. | Xie T et al. | β | 2019 | β |
| Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. | Struik D et al. | β | 2019 | β |
| Going Back to the Biology of FGF21: New Insights. | Lewis JE et al. | β | 2019 | β |
| Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1Ξ±-FGF21 axis in mice. | Aljohani A et al. | β | 2019 | β |
| Higher circulating adiponectin and lower orosomucoid were associated with postload glucose β€70 mg/dL, a possible inverse marker for dysglycemia, in young Japanese women. | Tsuboi A et al. | β | 2019 | β |
| Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease. | Peng Y et al. | β | 2019 | β |
| Low expression of brown and beige fat genes in subcutaneous tissues in obese patients. | Al-Amrani A et al. | β | 2019 | β |
| Lyophilized Maqui (<i>Aristotelia chilensis</i>) Berry Induces Browning in the Subcutaneous White Adipose Tissue and Ameliorates the Insulin Resistance in High Fat Diet-Induced Obese Mice. | Sandoval V et al. | β | 2019 | β |
| Marrow adipose tissue gradient is preserved through high protein diet and bed rest. A randomized crossover study. | Trudel G et al. | β | 2019 | β |
| Methionine restriction prevents onset of type 2 diabetes in NZO mice. | CastaΓ±o-Martinez T et al. | β | 2019 | β |
| Molecular Mechanisms Underlying Obesity-Induced Hypothalamic Inflammation and Insulin Resistance: Pivotal Role of Resistin/TLR4 Pathways. | Benomar Y et al. | β | 2019 | β |
| Omega 3 rich diet modulates energy metabolism via GPR120-Nrf2 crosstalk in a novel antioxidant mouse model. | Amos D et al. | β | 2019 | β |
| Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini-review. | Yuan D et al. | β | 2019 | β |
| Serum Levels of Meteorin-Like (Metrnl) Are Increased in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Are Associated with Insulin Resistance. | Wang K et al. | β | 2019 | β |
| The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism. | Cariello M et al. | β | 2019 | β |
| The FGF metabolic axis. | Li X | β | 2019 | β |
| The impact of keto-adaptation on exercise performance and the role of metabolic-regulating cytokines. | Sherrier M et al. | β | 2019 | β |
| The Role of Kupffer Cells as Mediators of Adipose Tissue Lipolysis. | Ma W et al. | β | 2019 | β |
| The roles of FGF21 in atherosclerosis pathogenesis. | Tabari FS et al. | β | 2019 | β |
| Acute loss of adipose tissue-derived adiponectin triggers immediate metabolic deterioration in mice. | Xia JY et al. | β | 2018 | β |
| Adiponectin AS lncRNA inhibits adipogenesis by transferring from nucleus to cytoplasm and attenuating Adiponectin mRNA translation. | Cai R et al. | β | 2018 | β |
| A high circulating FGF21 level as a prognostic marker in patients with acute myocardial infarction. | Chen H et al. | β | 2018 | β |
| A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. | Bao L et al. | β | 2018 | β |
| A low-protein diet exerts a beneficial effect on diabetic status and prevents diabetic nephropathy in Wistar fatty rats, an animal model of type 2 diabetes and obesity. | Kitada M et al. | β | 2018 | β |
| Cellular Stresses and Stress Responses in the Pathogenesis of Insulin Resistance. | Onyango AN | β | 2018 | β |
| Cholic Acid Supplementation of a High-Fat Obesogenic Diet Suppresses Hepatic Triacylglycerol Accumulation in Mice via a Fibroblast Growth Factor 21-Dependent Mechanism. | Ippagunta SM et al. | β | 2018 | β |
| Circulating fibroblast growth factor 21 in patients with liver cirrhosis. | Krautbauer S et al. | β | 2018 | β |
| Conditioned medium from contracting skeletal muscle cells reverses insulin resistance and dysfunction of endothelial cells. | Zhao Y et al. | β | 2018 | β |
| Curcumin and dietary polyphenol research: beyond drug discovery. | Jin TR | β | 2018 | β |
| Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down-regulation of phosphorylation of PPARΞ³ in 3T3-L1 cells. | Liu L et al. | β | 2018 | β |
| Effects of EPA and lipoic acid supplementation on circulating FGF21 and the fatty acid profile in overweight/obese women following a hypocaloric diet. | EscotΓ© X et al. | β | 2018 | β |
| Factors associated with cognitive impairment in elderly versus nonelderly patients with metabolic syndrome: the different roles of FGF21. | Phrommintikul A et al. | β | 2018 | β |
| FGF21 induced by carbon monoxide mediates metabolic homeostasis via the PERK/ATF4 pathway. | Joe Y et al. | β | 2018 | β |
| FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. | Pan X et al. | β | 2018 | β |
| FGF Family: From Drug Development to Clinical Application. | Hui Q et al. | β | 2018 | β |
| Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis. | BonDurant LD et al. | β | 2018 | β |
| Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice. | Fu Z et al. | β | 2018 | β |
| Fibroblast Growth Factor Binding Protein 3 (FGFBP3) impacts carbohydrate and lipid metabolism. | Tassi E et al. | β | 2018 | β |
| Fibroblast growth factors 19 and 21 in acute liver damage. | Shan Z et al. | β | 2018 | β |
| Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. | Gilroy CA et al. | β | 2018 | β |
| Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21. | Sawicki KT et al. | β | 2018 | β |
| Hepatocyte ALOXE3 is induced during adaptive fasting and enhances insulin sensitivity by activating hepatic PPARΞ³. | Higgins CB et al. | β | 2018 | β |
| Links Between Obesity-Induced Brain Insulin Resistance, Brain Mitochondrial Dysfunction, and Dementia. | Sripetchwandee J et al. | β | 2018 | β |
| Low- and high-protein diets do not alter exΒ vivo insulin action in skeletal muscle. | Li Z et al. | β | 2018 | β |
| LY2405319, an analog of fibroblast growth factor 21 ameliorates Ξ±-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. | Le CT et al. | β | 2018 | β |
| Maternal Serum and Breast Milk Adiponectin: The Association with Infant Adiposity Development. | Mohamad M et al. | β | 2018 | β |
| Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases. | Singh R et al. | β | 2018 | β |
| Myokines as Possible Therapeutic Targets in Cancer Cachexia. | Manole E et al. | β | 2018 | β |
| Periodized low protein-high carbohydrate diet confers potent, but transient, metabolic improvements. | Li Z et al. | β | 2018 | β |
| Regulation of Adipose Tissue Metabolism by the Endocannabinoid System. | van Eenige R et al. | β | 2018 | β |
| Retracted: Transplantation of brown adipose tissue inhibits atherosclerosis in apoE-/- mice: contribution of the activated FGF-21-adiponectin axis. | Kikai M et al. | β | 2018 | β |
| Serum hepatokines in dairy cows: periparturient variation and changes in energy-related metabolic disorders. | Wang J et al. | β | 2018 | β |
| Sleeve gastrectomy attenuates high fat diet-induced non-alcoholic fatty liver disease. | Pei E et al. | β | 2018 | β |
| TCF4/Ξ²-catenin complex is directly upstream of <i>FGF21</i> in mouse stomach cancer cells. | Pei J et al. | β | 2018 | β |
| The role of adipokines in skeletal muscle inflammation and insulin sensitivity. | Nicholson T et al. | β | 2018 | β |
| The role of FGF21 in type 1 diabetes and its complications. | Zhang J et al. | β | 2018 | β |
| Treatment of type 2 diabetes: future approaches. | Bailey CJ et al. | β | 2018 | β |
| Zinc alpha2 glycoprotein protects against obesity-induced hepatic steatosis. | Xiao XH et al. | β | 2018 | β |
| Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. | Rutkowski JM et al. | β | 2017 | β |
| Adipose angiotensin II type 1 receptor-associated protein ameliorates metabolic disorders via promoting adipose tissue adipogenesis and browning. | Luo C et al. | β | 2017 | β |
| Cell-based cytotoxicity assays for engineered nanomaterials safety screening: exposure of adipose derived stromal cells to titanium dioxide nanoparticles. | Xu Y et al. | β | 2017 | β |
| Circulating FGF21 in humans is potently induced by short term overfeeding of carbohydrates. | Lundsgaard AM et al. | β | 2017 | β |
| CXCL16 deficiency attenuates diabetic nephropathy through decreasing oxidative stress and inflammation. | Ye Y et al. | β | 2017 | β |
| Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats. | Liu L et al. | β | 2017 | β |
| Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets. | Chen Y et al. | β | 2017 | β |
| Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. | Wu W et al. | β | 2017 | β |
| Feedback Activation of Basic Fibroblast Growth Factor Signaling via the Wnt/Ξ²-Catenin Pathway in Skin Fibroblasts. | Wang X et al. | β | 2017 | β |
| FGF19, FGF21, and an FGFR1/Ξ²-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. | Lan T et al. | β | 2017 | β |
| FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process. | Salminen A et al. | β | 2017 | β |
| FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. | Fu Z et al. | β | 2017 | β |
| FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice. | Wu F et al. | β | 2017 | β |
| FGF21 deficiency is associated with childhood obesity, insulin resistance and hypoadiponectinaemia: The BCAMS Study. | Li G et al. | β | 2017 | β |
| FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis. | Mottillo EP et al. | β | 2017 | β |
| FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes. | Laeger T et al. | β | 2017 | β |
| FGF21 Mediates the Thermogenic and Insulin-Sensitizing Effects of Dietary Methionine Restriction but Not Its Effects on Hepatic Lipid Metabolism. | Wanders D et al. | β | 2017 | β |
| FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. | Sonoda J et al. | β | 2017 | β |
| FGF21 regulates melanogenesis in alpaca melanocytes<i>via</i>ERK1/2-Mediated MITF downregulation | Wang R et al. | β | 2017 | β |
| FGF21 regulates melanogenesis in alpaca melanocytes via ERK1/2-mediated MITF downregulation. | Wang R et al. | β | 2017 | β |
| FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms. | BonDurant LD et al. | β | 2017 | β |
| Fibroblast Growth Factor 21-Metabolic Role in Mice and Men. | Staiger H et al. | β | 2017 | β |
| Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis. | Kwok KHM et al. | β | 2017 | β |
| Fibroblast growth factor 21 night watch: advances and uncertainties in the field. | Kharitonenkov A et al. | β | 2017 | β |
| Fibroblast growth factor 21 reverses suppression of adiponectin expression via inhibiting endoplasmic reticulum stress in adipose tissue of obese mice. | Guo Q et al. | β | 2017 | β |
| From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. | Caputo T et al. | β | 2017 | β |
| Liver-adipose tissue crosstalk: A key player in the pathogenesis of glucolipid metabolic disease. | Ye DW et al. | β | 2017 | β |
| Measuring non-polyaminated lipocalin-2 for cardiometabolic risk assessment. | Yang K et al. | β | 2017 | β |
| Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. | Lin X et al. | β | 2017 | β |
| Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue. | Li F et al. | β | 2017 | β |
| Nutrition, metabolism, and targeting aging in nonhuman primates. | Balasubramanian P et al. | β | 2017 | β |
| Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals. | Rajan S et al. | β | 2017 | β |
| Rapamycin-ameliorated diabetic symptoms involved in increasing adiponectin expression in diabetic mice on a high-fat diet. | Gong FH et al. | β | 2017 | β |
| Regulation of longevity by FGF21: Interaction between energy metabolism and stress responses. | Salminen A et al. | β | 2017 | β |
| Role of Circulating Fibroblast Growth Factor 21 Measurement in Primary Prevention of Coronary Heart Disease Among Chinese Patients With Type 2 Diabetes Mellitus. | Lee CH et al. | β | 2017 | β |
| Rush to the fire: FGF21 extinguishes metabolic stress, metaflammation and tissue damage. | Luo Y et al. | β | 2017 | β |
| Serum FGF21 Levels in Obese Korean Children and Adolescents. | Baek J et al. | β | 2017 | β |
| Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes. | Woo YC et al. | β | 2017 | β |
| Sex-specific association between fibroblast growth factor 21 and type 2 diabetes: a nested case-control study in Singapore Chinese men and women. | Wang Y et al. | β | 2017 | β |
| The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity. | Huang Z et al. | β | 2017 | β |
| The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-Ξ± agonist-induced amelioration of metabolic disorders in obese mice. | Goto T et al. | β | 2017 | β |
| Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. | Greuter T et al. | β | 2017 | β |
| The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes. | Izaguirre M et al. | β | 2017 | β |
| The role of fibroblast growth factor 21 in atherosclerosis. | Kokkinos J et al. | β | 2017 | β |
| To be or not to be cell autonomous? Autophagy says both. | Fenouille N et al. | β | 2017 | β |
| Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. | Sente T et al. | β | 2016 | β |
| Adipose-derived lipocalin 14 alleviates hyperglycaemia by suppressing both adipocyte glycerol efflux and hepatic gluconeogenesis in mice. | Lee JT et al. | β | 2016 | β |
| A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. | Talukdar S et al. | β | 2016 | β |
| Central Resistin/TLR4 Impairs Adiponectin Signaling, Contributing to Insulin and FGF21 Resistance. | Benomar Y et al. | β | 2016 | β |
| Circulating Fibroblast Growth Factor 21 (Fgf21) as Diagnostic and Prognostic Biomarker in Renal Cancer. | Knott ME et al. | β | 2016 | β |
| Circulating Fibroblast Growth Factor 21 Is A Sensitive Biomarker for Severe Ischemia/reperfusion Injury in Patients with Liver Transplantation. | Ye D et al. | β | 2016 | β |
| Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health. | Fontana L et al. | β | 2016 | β |
| Distribution of fibroblast growth factors and their roles in skin fibroblast cell migration. | Song YH et al. | β | 2016 | β |
| Dose-Dependent Metabolic Reprogramming and Differential Gene Expression in TCDD-Elicited Hepatic Fibrosis. | Nault R et al. | β | 2016 | β |
| Expression and purification of FGF21 in Pichia pastoris and its effect on fibroblast-cell migration. | Song Y et al. | β | 2016 | β |
| Feeding a Modified Fish Diet to Bottlenose Dolphins Leads to an Increase in Serum Adiponectin and Sphingolipids. | Sobolesky PM et al. | β | 2016 | β |
| FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats. | Sa-Nguanmoo P et al. | β | 2016 | β |
| FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency. | Dollet L et al. | β | 2016 | β |
| FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues. | Schlein C et al. | β | 2016 | β |
| Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21. | Dunshee DR et al. | β | 2016 | β |
| Fibroblast growth factor 21 - a key player in cardiovascular disorders? | Lenart-LipiΕska M et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus. | So WY et al. | β | 2016 | β |
| Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. | Gong Q et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 Mediates Glycemic Regulation by Hepatic JNK. | Vernia S et al. | β | 2016 | β |
| Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions. | Guo Y et al. | β | 2016 | β |
| Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. | Jin L et al. | β | 2016 | β |
| Fibroblast growth factors, old kids on the new block. | Li X et al. | β | 2016 | β |
| Future glucose-lowering drugs for type 2 diabetes. | Bailey CJ et al. | β | 2016 | β |
| Hepatic Fatty Acid Oxidation Restrains Systemic Catabolism during Starvation. | Lee J et al. | β | 2016 | β |
| Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes. | Donate-Correa J et al. | β | 2016 | β |
| Key data from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. | Coughlan R et al. | β | 2016 | β |
| Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. | Oh KJ et al. | β | 2016 | β |
| Metabolic effects of basic fibroblast growth factor in streptozotocin-induced diabetic rats: A <sup>1</sup>H NMR-based metabolomics investigation. | Lin X et al. | β | 2016 | β |
| Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis. | Markan KR et al. | β | 2016 | β |
| Methionine restriction on lipid metabolism and its possible mechanisms. | Zhou X et al. | β | 2016 | β |
| Modulation of energy balance by fibroblast growth factor 21. | Cuevas-Ramos D et al. | β | 2016 | β |
| mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes. | Minard AY et al. | β | 2016 | β |
| Muscle mitochondrial stress adaptation operates independently of endogenous FGF21 action. | Ost M et al. | β | 2016 | β |
| Nuclear receptors and AMPK: can exercise mimetics cure diabetes? | Wall CE et al. | β | 2016 | β |
| Nuclear receptors and nonalcoholic fatty liver disease. | Cave MC et al. | β | 2016 | β |
| Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds. | PΓ©rez-MartΓ A et al. | β | 2016 | β |
| PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates. | Thompson WC et al. | β | 2016 | β |
| Pilot-scale production and characterization of PEGylated human FGF-21 analog. | Ye X et al. | β | 2016 | β |
| Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. | Panera N et al. | β | 2016 | β |
| Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease. | Itoh N et al. | β | 2016 | β |
| Single ingestion of soy Ξ²-conglycinin induces increased postprandial circulating FGF21 levels exerting beneficial health effects. | Hashidume T et al. | β | 2016 | β |
| Targeting adipose tissue in the treatment of obesity-associated diabetes. | Kusminski CM et al. | β | 2016 | β |
| The emerging role of fibroblast growth factor 21 in diabetic nephropathy. | Mao S et al. | β | 2016 | β |
| The FGF21-adiponectin axis in controlling energy and vascular homeostasis. | Hui X et al. | β | 2016 | β |
| The multimerization and secretion of adiponectin are regulated by TNF-alpha. | He Y et al. | β | 2016 | β |
| The progress and challenges in metabolic research in China. | Xu L et al. | β | 2016 | β |
| Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. | Degirolamo C et al. | β | 2016 | β |
| The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease. | Martins IJ | β | 2016 | β |
| The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. | Erion DM et al. | β | 2016 | β |
| Troxerutin Attenuates Enhancement of Hepatic Gluconeogenesis by Inhibiting NOD Activation-Mediated Inflammation in High-Fat Diet-Treated Mice. | Zhang Z et al. | β | 2016 | β |
| Understanding the Physiology of FGF21. | Fisher FM et al. | β | 2016 | β |
| Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21. | Lu P et al. | β | 2015 | β |
| Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high-fat diet feeding in mice. | Liu Y et al. | β | 2015 | β |
| A microfluidic interface for the culture and sampling of adiponectin from primary adipocytes. | Godwin LA et al. | β | 2015 | β |
| Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. | Park SE et al. | β | 2015 | β |
| Circulating FGF19 and FGF21 surge in early infancy from infra- to supra-adult concentrations. | SΓ‘nchez-Infantes D et al. | β | 2015 | β |
| Circulating FGF21 levels are related to nutritional status and metabolic but not hormonal disturbances in polycystic ovary syndrome. | Olszanecka-Glinianowicz M et al. | β | 2015 | β |
| Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice. | Ye X et al. | β | 2015 | β |
| Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1. | Samms RJ et al. | β | 2015 | β |
| Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. | Itoh N et al. | β | 2015 | β |
| Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. | Jiao Y et al. | β | 2015 | β |
| FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs. | Kim KH et al. | β | 2015 | β |
| FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. | Joki Y et al. | β | 2015 | β |
| FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. | Yan X et al. | β | 2015 | β |
| FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance. | Bernardo B et al. | β | 2015 | β |
| FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. | Zhao C et al. | β | 2015 | β |
| FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties. | Kharitonenkov A et al. | β | 2015 | β |
| Fibroblast Growth Factor 21 Analogs for Treating Metabolic Disorders. | Zhang J et al. | β | 2015 | β |
| Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice. | Yan X et al. | β | 2015 | β |
| Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. | Kim SH et al. | β | 2015 | β |
| Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. | Lin Z et al. | β | 2015 | β |
| Fibroblast Growth Factor Signaling in Metabolic Regulation. | Nies VJ et al. | β | 2015 | β |
| Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. | Qin Y et al. | β | 2015 | β |
| GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. | Liu J et al. | β | 2015 | β |
| Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. | Camporez JP et al. | β | 2015 | β |
| Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis. | Lawan A et al. | β | 2015 | β |
| Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue. | Asrih M et al. | β | 2015 | β |
| Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. | So WY et al. | β | 2015 | β |
| Mice lacking neutral amino acid transporter B(0)AT1 (Slc6a19) have elevated levels of FGF21 and GLP-1 and improved glycaemic control. | Jiang Y et al. | β | 2015 | β |
| Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. | Zhang F et al. | β | 2015 | β |
| Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21. | Assini JM et al. | β | 2015 | β |
| New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. | Beuers U et al. | β | 2015 | β |
| Novel Mediators of Adipose Tissue and Muscle Crosstalk. | Indrakusuma I et al. | β | 2015 | β |
| Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. | Komori T et al. | β | 2015 | β |
| Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes. | Lu J et al. | β | 2015 | β |
| Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. | Weng Y et al. | β | 2015 | β |
| Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and Ξ²-klotho expression decrease with fasting in northern elephant seals. | Suzuki M et al. | β | 2015 | β |
| Practical prospects for boosting hepatic production of the "pro-longevity" hormone FGF21. | McCarty MF | β | 2015 | β |
| Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1Ξ± pathway. | Ji K et al. | β | 2015 | β |
| Stress signaling between organs in metazoa. | Owusu-Ansah E et al. | β | 2015 | β |
| Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/Ξ²Klotho Complex. | Kolumam G et al. | β | 2015 | β |
| The Fibroblast Growth Factor signaling pathway. | Ornitz DM et al. | β | 2015 | β |
| The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective. | Liu JJ et al. | β | 2015 | β |
| The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. | Liu J et al. | β | 2015 | β |
| The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome. | Zhang Z et al. | β | 2015 | β |
| Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. | Owen BM et al. | β | 2015 | β |
| TM-25659-Induced Activation of FGF21 Level Decreases Insulin Resistance and Inflammation in Skeletal Muscle via GCN2 Pathways. | Jung JG et al. | β | 2015 | β |
| Transcriptional control and hormonal response of thermogenic fat. | Emont MP et al. | β | 2015 | β |
| Action and therapeutic potential of oxyntomodulin. | Pocai A | β | 2014 | β |
| Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. | Kumar P et al. | β | 2014 | β |
| Adiponectin as a tissue regenerating hormone: more than a metabolic function. | Fiaschi T et al. | β | 2014 | β |
| Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. | Markan KR et al. | β | 2014 | β |
| Commentary: FGF21 holds promises for treating obesity-related insulin resistance and hepatosteatosis. | Alisi A et al. | β | 2014 | β |
| Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. | Suh JM et al. | β | 2014 | β |
| Energy metabolism in the liver. | Rui L | β | 2014 | β |
| FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. | Owen BM et al. | β | 2014 | β |
| FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases. | Itoh N | β | 2014 | β |
| FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases. | Kim KH et al. | β | 2014 | β |
| FGF21-based pharmacotherapy--potential utility for metabolic disorders. | Gimeno RE et al. | β | 2014 | β |
| FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. | Liang Q et al. | β | 2014 | β |
| Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids. | Villarroya J et al. | β | 2014 | β |
| Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases. | Cheung BM et al. | β | 2014 | β |
| Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes. | Lee DV et al. | β | 2014 | β |
| Fibroblast growth factor 21 is regulated by the IRE1Ξ±-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. | Jiang S et al. | β | 2014 | β |
| Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. | Fisher FM et al. | β | 2014 | β |
| Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. | Zhang J et al. | β | 2014 | β |
| GCN2 and FGF21 are likely mediators of the protection from cancer, autoimmunity, obesity, and diabetes afforded by vegan diets. | McCarty MF | β | 2014 | β |
| Hepatic FGF21 production is increased in late pregnancy in the mouse. | Cui Y et al. | β | 2014 | β |
| Influence of feeding graded levels of canned sardines on the inflammatory markers and tissue fatty acid composition of Wistar rats. | Rodrigues PO et al. | β | 2014 | β |
| Inventing new medicines: The FGF21 story. | Kharitonenkov A et al. | β | 2014 | β |
| Liver but not adipose tissue is responsive to the pattern of enteral feeding. | Otero YF et al. | β | 2014 | β |
| LT175 is a novel PPARΞ±/Ξ³ ligand with potent insulin-sensitizing effects and reduced adipogenic properties. | Gilardi F et al. | β | 2014 | β |
| Mechanisms of increased in vivo insulin sensitivity by dietary methionine restriction in mice. | Stone KP et al. | β | 2014 | β |
| Myokines in insulin resistance and type 2 diabetes. | Eckardt K et al. | β | 2014 | β |
| Nuclear receptors and metabolism: from feast to famine. | Hong SH et al. | β | 2014 | β |
| Oral administration of soybean peptide Vglycin normalizes fasting glucose and restores impaired pancreatic function in Type 2 diabetic Wistar rats. | Jiang H et al. | β | 2014 | β |
| Physiology and Endocrinology Symposium: FGF21: Insights into mechanism of action from preclinical studies. | Antonellis PJ et al. | β | 2014 | β |
| Pioglitazone ameliorates the lowered exercise capacity and impaired mitochondrial function of the skeletal muscle in type 2 diabetic mice. | Takada S et al. | β | 2014 | β |
| Regulation of energy metabolism by long-chain fatty acids. | Nakamura MT et al. | β | 2014 | β |
| Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic Ξ² cells and adipocytes. | Tao C et al. | β | 2014 | β |
| Roles of FGFs as Adipokines in Adipose Tissue Development, Remodeling, and Metabolism. | Ohta H et al. | β | 2014 | β |
| Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. | Lin Y et al. | β | 2014 | β |
| Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine. | Keipert S et al. | β | 2014 | β |
| Sphingolipid metabolites in inflammatory disease. | Maceyka M et al. | β | 2014 | β |
| Supplementation with conjugated linoleic acids extends the adiponectin deficit during early lactation in dairy cows. | Singh SP et al. | β | 2014 | β |
| The biochemistry and cell biology of aging: metabolic regulation through mitochondrial signaling. | Long YC et al. | β | 2014 | β |
| The control of insulin secretion by adipokines: current evidence for adipocyte-beta cell endocrine signalling in metabolic homeostasis. | Cantley J | β | 2014 | β |
| The impact of dietary methionine restriction on biomarkers of metabolic health. | Orgeron ML et al. | β | 2014 | β |
| The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. | Park S et al. | β | 2014 | β |
| The PPARΞ±-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. | Vernia S et al. | β | 2014 | β |
| What we talk about when we talk about fat. | Rosen ED et al. | β | 2014 | β |
| Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. | Camporez JP et al. | β | 2013 | β |
| Deficiency of metabolic regulator FGFR4 delays breast cancer progression through systemic and microenvironmental metabolic alterations. | Luo Y et al. | β | 2013 | β |
| Dichotomous roles of leptin and adiponectin as enforcers against lipotoxicity during feast and famine. | Unger RH et al. | β | 2013 | β |
| Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. | Muise ES et al. | β | 2013 | β |
| FGF21 drives a shift in adipokine tone to restore metabolic health. | Adams AC et al. | β | 2013 | β |
| FGF21 mimetic shows therapeutic promise. | Reitman ML | β | 2013 | β |
| Fibrate therapy and circulating adiponectin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. | Sahebkar A et al. | β | 2013 | β |
| Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. | Adams AC et al. | β | 2013 | β |
| LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys. | Adams AC et al. | β | 2013 | β |
| Metabolism: Adiponectin---a mediator of specific metabolic actions of FGF21. | Goetz R | β | 2013 | β |
| Stressed Liver and Muscle Call on Adipocytes with FGF21. | Luo Y et al. | β | 2013 | β |
| The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. | Gaich G et al. | β | 2013 | β |